

Argos Therapeutics

Pharma & biotech
17 July 2014

Second-generation dendritic cell therapy

Encouraging Phase II survival data at ASCO for Argos's lead product AGS-003 in mRCC have failed to move the stock from levels close to its 52-week low and below its IPO price in February 2014. While investors clearly remain cautious of dendritic cell transfer therapies, data expected mid-2014 (Phase IIb for AGS-004 in HIV) and at end 2015 (interim Phase III for AGS-003 in mRCC) could provide upside from the current EV of \$71m.

AGS-003 in mRCC encouraging; fast-track Phase III

Recent Phase II data at ASCO in mRCC with AGS-003 were encouraging, albeit small scale (n = 21). Overall survival (OS) was 30.2 months for AGS-003 + Pfizer's Sutent vs OS in comparator trials of 15.6 months for AGS-003 alone or 14.7 months for first-line treatment with Sutent/other tyrosine kinase inhibitors (International mRCC Database Consortium data). Argos is currently enrolling the 450-patient Phase III ADAPT trial in mRCC and plans to initiate several Phase IIa trials in other solid tumours during 2014.

AGS-004 Phase II data in HIV imminent

Argos's AGS-004 immunotherapy for HIV is in a 53-patient Phase IIb trial, which is fully funded by a \$39.3m NIH contract and reports in mid-2014. If positive, it will allow Argos to initiate two further Phase IIa trials in H214 looking at HIV eradication in adults and long-term viral control in paediatric patients (data due in 2016).

Platform technology with broad applicability

Argos's Arcelis technology consists of injecting a patient's own dendritic cells with RNA from their tumour (or virus) back into them to stimulate an immune response to the disease. Dendritic cells are key to antigen presentation and the goal is to overcome disease-induced immunosuppression and generate immune memory without the toxicity of many oral therapies. Progress with AGS-003 and AGS-004 indicates the platform's potential in oncology and infectious diseases.

Low EV reflects market caution

Argos's EV is only \$71m, including cash of \$83m after the IPO in February 2014. The market appears to be affording little value to the pipeline, perhaps reflecting caution following the unfulfilled promise of Dendreon's Provenge in prostate cancer. Valuation inflection points are likely to be around data publication for AGS-003 (interim Phase III in mRCC end-2015, final data 2016) and AGS-004 in mid-2014.


Consensus estimates

Year end	Revenue (\$m)	PBT (\$m)	EPS (\$)	DPS (\$)	P/E (x)	Yield (%)
12/12	7.0	(10.5)	(54.6)	0.0	N/A	N/A
12/13	4.4	(23.9)	(147.4)	0.0	N/A	N/A
12/14e	4.2	(36.0)	(3.1)	0.0	N/A	N/A
12/15e	3.2	(41.5)	(3.1)	0.0	N/A	N/A

Source: Bloomberg

Price **\$7.81**
Market cap **\$154m**

Share price graph



Share details

Code **ARGS**
 Listing **NASDAQ**
 Shares in issue **19.7**

Business description

Argos Therapeutics, a North Carolina-based biopharmaceutical company, develops 'personalized immunotherapies' using its Arcelis technology based on autologous dendritic cell (DC) transfer. Its product candidates include AGS-003 in Phase III for the treatment of metastatic renal cell carcinoma (mRCC), and AGS-004 in Phase IIb for HIV.

Bull

- mRCC and HIV are significant markets, with current therapies often poorly tolerated.
- Sufficient cash (\$83m) to fund AGS-003 mRCC trials to filing; AGS-004 HIV trials funded by NIH.
- Arcelis technology should offer improvements over previous approaches including only requiring a single isolation of cells from the patient and the ability to load DCs with multiple disease antigens.

Bear

- Use of dendritic cells as immunotherapy is relatively uncharted.
- Dendreon's first-generation DC product Provenge for prostate cancer had disappointing sales.
- Competition from oral products and other immunotherapies for mRCC such as Immutec's cancer vaccine, IMA-901, in Phase III.

Analysts

Dr Charlotte Hetzel +44 (0)20 3077 5700
 Dr Philippa Gardner +44 (0)20 3681 2521

healthcare@edisongroup.com

EDISON QUICKVIEWS ARE NORMALLY ONE OFF PUBLICATIONS WITH NO COMMITMENT TO WRITING ANY FOLLOW UP. QUICKVIEW NOTES USE CONSENSUS EARNINGS ESTIMATES.

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Copyright 2014 Edison Investment Research Limited. All rights reserved. This report has been prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") (c) FTSE [2013]. "FTSE(i)" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.